COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression

University of California Irvine (UCI)

Status: Withdrawn

Conditions: Androgen Receptor Gene Overexpression; Covid19

Treatments: Genetic: COVID-19 Androgen Sensitivity Test (CoVAST)

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04530500

20205907

Details and patient eligibility

About

This research study will evaluate the association of Androgen Receptor (AR) gene expression and COVID-19 disease severity and mortality. The research procedure involves collection of a single saliva sample which will be mailed to the participants by the study team. This saliva will be used in a COVID-19 Androgen Sensitivity Test (CoVAST) which will detect AR gene expression. Eligible participants are males, at least 18 years or older, and have tested positive for COVID-19.

Sex: Male

Ages: 18 to 90 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male over the age of 18
• Laboratory confirmed SARS-CoV-2 infection
• Able to give verbal informed consent

Exclusion criteria

• Unable to give informed consent
• Diagnosed with an additional respiratory co-infection
• XXY males

Trial design

0 participants in 2 patient groups

Arm 1

Description:

Males first tested positive for SARS-CoV-2 at the site (medical center) with CAG length \<24 (based on the CoVAST Test)

Treatment:

Genetic: COVID-19 Androgen Sensitivity Test (CoVAST)

Arm 2

Description:

Males first tested for SARS-CoV-2 at the site (medical center) with CAG length \>=24 (based on the CoVAST Test)

Treatment:

Genetic: COVID-19 Androgen Sensitivity Test (CoVAST)